Tom Lillie

574 total citations
27 papers, 439 citations indexed

About

Tom Lillie is a scholar working on Hematology, Oncology and Genetics. According to data from OpenAlex, Tom Lillie has authored 27 papers receiving a total of 439 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Hematology, 11 papers in Oncology and 5 papers in Genetics. Recurrent topics in Tom Lillie's work include Erythropoietin and Anemia Treatment (17 papers), Iron Metabolism and Disorders (6 papers) and Cancer Research and Treatments (5 papers). Tom Lillie is often cited by papers focused on Erythropoietin and Anemia Treatment (17 papers), Iron Metabolism and Disorders (6 papers) and Cancer Research and Treatments (5 papers). Tom Lillie collaborates with scholars based in United States, United Kingdom and Belgium. Tom Lillie's co-authors include John A. Glaspy, Tudor–Eliade Ciuleanu, Robert E. Smith, Martin Šmakal, Heinz Ludwig, Tamás Pintér, Li Chen, Matti Aapro, Wolfgang Schuette and Petr Zatloukal and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Tom Lillie

26 papers receiving 422 citations

Peers

Countries citing papers authored by Tom Lillie

Since Specialization

Citations

This map shows the geographic impact of Tom Lillie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tom Lillie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tom Lillie more than expected).

Fields of papers citing papers by Tom Lillie

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tom Lillie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tom Lillie. The network helps show where Tom Lillie may publish in the future.

Co-authorship network of co-authors of Tom Lillie

This figure shows the co-authorship network connecting the top 25 collaborators of Tom Lillie. A scholar is included among the top collaborators of Tom Lillie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tom Lillie. Tom Lillie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	First-in-human clinical outcomes with NG-350A, an anti-CD40 expressing tumor-selective vector designed to remodel immunosuppressive tumor microenvironments 2024 ·Journal for ImmunoTherapy of Cancer ·Aung Naing, Danny N. Khalil, Oliver Rosen, (unknown), Tom Lillie, (unknown), Andrea Stacey, Matthew C. Thomas, Lee S. Rosen	5
2	Safety and efficacy of the tumor-selective adenovirus enadenotucirev, in combination with nivolumab, in patients with advanced/metastatic epithelial cancer: a phase I clinical trial (SPICE) 2023 ·Journal for ImmunoTherapy of Cancer ·Marwan Fakih, Wael A. Harb, Daruka Mahadevan, Hani M. Babiker, Jordan Berlin, Tom Lillie, David Krige, (unknown), Chris D. Cox, Minesh Patel, (unknown), Mark Powell, Lee S. Rosen	28
3	A tumor-selective adenoviral vector platform induces transient antiphospholipid antibodies, without increased risk of thrombosis, in phase 1 clinical studies 2023 ·Investigational New Drugs ·Danny N. Khalil, (unknown), Lee S. Rosen, Tom Lillie, Andrea Stacey, (unknown), Gerald A. Soff	7
4	762 First-in-human phase 1a study of NG-641, a tumour-selective vector expressing a FAP-TAc bispecific antibody and immune enhancer module, in patients with metastatic/advanced epithelial tumours (STAR) 2022 ·Regular and Young Investigator Award Abstracts ·George R. Simon, Vivek Subbiah, Lee S. Rosen, Heinz‐Josef Lenz, Haeseong Park, Minesh Patel, David Miles, (unknown), (unknown), David Krige, Mark Powell, Tom Lillie	7
5	Abstract CT214: A multicenter phase 1a/b study of NG-641, a tumor-selective transgene-expressing adenoviral vector, and nivolumab in patients with metastatic or advanced epithelial tumors (NEBULA) 2022 ·Cancer Research ·Tom Lillie, Eileen E. Parkes, Christian H. Ottensmeier, David Krige, (unknown), (unknown), Matthew C. Thomas, Lee S. Rosen	4
6	342 Combining enadenotucirev and nivolumab increased tumour immune cell infiltration/activation in patients with microsatellite-stable/instability-low metastatic colorectal cancer in a phase 1 study 2021 ·Regular and Young Investigator Award Abstracts ·David Krige, Marwan Fakih, Lee S. Rosen, Ding Wang, Wael A. Harb, Hani M. Babiker, Jordan Berlin, Gianfranco Di Genova, David Miles, Mark Powell, Minesh Patel, (unknown), R. H. Brown, Tom Lillie	2
7	437 A multicentre phase 1b study of NG-641, a novel transgene-armed and tumour-selective adenoviral vector, and pembrolizumab as neoadjuvant treatment for squamous cell carcinoma of the head and neck 2021 ·Regular and Young Investigator Award Abstracts ·Christian H. Ottensmeier, Mererid Evans, Emma V. King, Ioannis Karydis, Tom Lillie, David Krige, Jenny Lee, Matthew C. Thomas, Kevin J. Harrington	4
8	1011P FORTITUDE phase I study of NG-350A, a novel tumour-selective adenoviral vector expressing an anti-CD40 agonist antibody: Monotherapy dose escalation results 2021 ·Annals of Oncology ·Aung Naing, Lee S. Rosen, (unknown), Danny N. Khalil, Justine Davies, David Miles, (unknown), Paul Cockle, Brian Champion, David Krige, Tom Lillie	4
9	329 Prolonged overall survival (OS) in patients with metastatic colorectal cancer (mCRC) in SPICE, a phase I study of enadenotucirev in combination with nivolumab 2020 ·SHILAP Revista de lepidopterología ·Tom Lillie, Andrew Stone, (unknown), R. H. Brown, Andrew J. Fox, Eirini Bournazou, John Beadle	2
10	Comparison of darbepoetin alfa dosed weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in patients receiving multicycle chemotherapy in a randomized, phase 2, open-label trial 2010 ·BMC Cancer ·Lee S. Schwartzberg, Ronald L. Burkes, B. Mirtsching, (unknown), Peter T. Silberstein, Lorrin Yee, (unknown), Tom Lillie	7
11	Darbepoetin Alfa for the Treatment of Anemia in Patients With Active Cancer Not Receiving Chemotherapy or Radiotherapy: Results of a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study 2008 ·Journal of Clinical Oncology ·Robert E. Smith, Matti Aapro, Heinz Ludwig, Tamás Pintér, Martin Šmakal, Tudor–Eliade Ciuleanu, Li Chen, Tom Lillie, John A. Glaspy	154
12	Safety and Efficacy of Darbepoetin Alfa in Previously Untreated Extensive-Stage Small-Cell Lung Cancer Treated With Platinum Plus Etoposide 2008 ·Journal of Clinical Oncology ·Robert Pirker, Rodryg Ramlau, Wolfgang Schuette, Petr Zatloukal, Irene Ferreira, Tom Lillie, (unknown)	93
13	A phase II, randomized, open-label study to assess the efficacy of extended-dose schedule administration of darbepoetin alfa in cancer patients with chemotherapy-induced anemia 2007 ·Lee S. Schwartzberg, (unknown), Lorrin Yee, B. Mirtsching, Veena Charu, Hung‐Ming Lam, Tom Lillie, Ronald L. Burkes, Peter T. Silberstein	1
14	PD6-3-6: A phase 3 randomized, double blind, placebo-controlled study of patients with previously untreated extensive-stage small cell lung cancer (SCLC) treated with platinum plus etoposide chemotherapy with or without darbepoetin alfa 2007 ·Journal of Thoracic Oncology ·Robert Pirker, Rodryg Ramlau, Wolfgang Schuette, Petr Zatloukal, Irene Ferreira, Tom Lillie, Johan Vansteenkiste	3
15	1120 POSTER Evaluation of the association between hemoglobin (Hb) events and safety outcomes in cancer patients (pts) with chemotherapy-induced anemia (CIA): an integrated analysis of patient-level data from 6 randomized, placebo-controlled trials (RCTs) of darbepoetin alfa (DA) 2007 ·European Journal of Cancer Supplements ·John A. Glaspy, Anders Österborg, H. Ludwig, A. Fleishman, Tom Lillie, Tamás Sütö, J. Crawford	10
16	The Effect of Hemoglobin (Hb) Level at ESA Initiation on Outcomes in Cancer Patients (pts) with Chemotherapy-Induced Anemia (CIA): A Patient-Based Meta-Analysis from 6 Randomized, Placebo-Controlled Trials (RCTs) of Darbepoetin alfa (DA). 2007 ·Blood ·Jeffrey Crawford, David H. Henry, Johan Vansteenkiste, Heinz Ludwig, Tom Lillie, A. Fleishman, John A. Glaspy	1
17	Darbepoetin Alfa Administered Every Three Weeks Is Effective for the Treatment of Chemotherapy-Induced Anemia 2006 ·The Oncologist ·Ralph V. Boccia, Imtiaz A. Malik, (unknown), Stephen P. Kahanic, (unknown), Tom Lillie, Dianne Tomita, Billy Clowney, Peter T. Silberstein	31
18	Treating Anemia of Cancer with Darbepoetin Alfa Administered Every 4 Weeks: Final Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study in Cancer Patients Not Receiving Chemotherapy and/or Radiotherapy. 2006 ·Blood ·David Gordon, Gwen Nichols, (unknown), Hung‐Ming Lam, Tom Lillie, Carole B. Miller	11
19	Effect of Dose Reductions on Response to 500-μg Darbepoetin alfa Administered Once Every 3 Weeks for the Treatment of Chemotherapy-Induced Anemia: Analysis from a Randomized, Double-Blind, Active-Controlled Trial. 2005 ·Blood ·Jean-Luc Canon, Johan Vansteenkiste, G. Bodoky, (unknown), Laurent Bastit, Irene Ferreira, Tom Lillie	1
20	Effects of Dose Adjustment Rules on Safety during Erythropoietic Therapy: A Retrospective Analysis of Darbepoetin alfa Administered Either Every 3 Weeks or Weekly. 2005 ·Blood ·Michael Hedenus, Jean-Luc Canon, Dusan Kotasek, Tom Lillie, Lisa Hendricks, Bin Yao, Johan Vansteenkiste	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact